IntelGenx and RedHill Biopharma Announce Acceptance for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
  • The German Federal Institute for Drugs and Medical Devices ("BfArM") has validated the European Marketing Authorization Application submitted for RIZAPORT™ and initiated its formal review of the application on November 25, 2014
  • IntelGenx and RedHill continue to work with the FDA to resolve the remaining Chemistry, Manufacturing and Controls ("CMC") issues and secure a  compliant source of the raw material, in order to advance potential FDA approval of the U.S. New Drug Application submitted by the companies
  • RIZAPORT™ oral thin film formulation of rizatriptan for acute migraines presents an attractive therapeutic alternative for many migraine patients, including those suffering from migraine-related nausea, due to its convenient dosing, lack of need for water intake and pleasant flavoring    

SAINT LAURENT, Quebec, Dec. 1, 2014 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX ) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focused on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq: RDHL ) (TASE: RDHL ) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, that the German Federal Institute for Drugs and Medical Devices ("BfArM") validated the Marketing Authorization Application ("MAA") for RIZAPORT™, an oral thin film formulation of rizatriptan for acute migraines, and has initiated the formal review process of the application on November 25, 2014. BfArM's potential feedback regarding the MAA is expected during the second half of 2015.

RIZAPORT™ oral thin film does not require the patient to swallow a pill or consume water and presents an attractive therapeutic alternative for many migraine patients, including those who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population¹.

The MAA was submitted under the European Mutual Recognition Procedure with Germany as the reference member state and Luxemburg as the Concerned Member State. The submission is supported by several studies and follows a positive scientific advice meeting with the BfArM.

IntelGenx and RedHill submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in March 2013 seeking marketing approval of RIZAPORT™ in the U.S. Following a complete response letter received from the FDA in February 2014, which raised questions primarily related to CMC, IntelGenx and RedHill reported that they believe that FDA approval of the RIZAPORT™ NDA is subject to the satisfactory resolution of the remaining CMC questions, as well as securing a compliant source of the raw material. Accordingly, the companies continue to work with the FDA in order to address and resolve all remaining CMC questions and to secure a compliant source of the raw material.

About RIZAPORT™:

RIZAPORT™ is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt®. Marketing applications for RIZAPORT™ have been filed both in the U.S. (NDA filed in March 2013) and in Europe (MAA filed in October 2014). Rizatriptan is considered one of the most effective oral triptans, a class of molecules that constrict blood vessels in the brain to relieve swelling and other migraine symptoms. The worldwide annual sales of triptans were estimated to have exceeded $1 billion in 2013².

RIZAPORT™ is based on IntelGenx' proprietary VersaFilm™ technology. It dissolves rapidly and releases its active ingredient in the mouth, leading to an efficient absorption of the drug through the gastro intestinal tract. The administration method of the RIZAPORT™ oral thin film which does not require the patient to swallow a pill or consume water, along with its pleasant flavoring, presents an attractive therapeutic alternative for many migraine patients, including those who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population³.

About IntelGenx:

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com .

About RedHill Biopharma Ltd.:

RedHill Biopharma Ltd. (Nasdaq: RDHL ) (TASE: RDHL ) is an emerging Israeli biopharmaceutical company focused on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. RedHill's current pipeline of proprietary products includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection, with an ongoing first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease, with an ongoing first Phase III study; (iii) RHB-102 - a once-daily oral pill formulation of ondansetron with a Phase III study in the U.S. for acute gastroenteritis and gastritis and a planned European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting; (iv) RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) MESUPRON™ - a Phase II-stage uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers; (vi) RP101 - currently subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; (vii) RIZAPORT™ (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines with a U.S. NDA currently under discussions with the FDA and a European marketing application submitted in October 2014; and (viii) RHB-101 - a once-daily oral pill formulation of the cardio drug carvedilol. For more information please visit www.redhillbio.com

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K for the fiscal year ended December 31, 2013, filed with the United States Securities and Exchange Commission and available at www.sec.gov , and also filed with Canadian securities regulatory authorities and www.sedar.com . IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.

1 Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. (2013) Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study, Headache.2013 Jan;53(1):93-103 
2 EvaluatePharma, 2013 WW annual sales by pharmacological class, 5-HT1B (serotonin) & 5HT1D (serotonin) agonist
3 Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. (2013) Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study, Headache.2013 Jan;53(1):93-103

Investor Contact: COCKRELL GROUP T: 877.889.1972 cockrellgroup.com Company Contact: Dr. Horst G. Zerbe, President and CEO IntelGenx Technologies Corp. T: +1 514-331-7440 (ext. 201) F: +1 514-331-0436 www.intelgenx.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 165

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 75

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 114

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 7

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 129

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
Markel's $2.5 Billion Buyback Adds Capital Flexibility

Updated Category News Views 86

A Large Checkbook, Not a Purchase Order Markel just handed management another $2.5 billion of repurchase firepower, and that deserves attention without the usual buyback cheerleading. The Board approved an increase to the existing authorization on November 18, 2026. That is a meaningful capital-allocation signal from a company built around specialty insurance,...

Continue Reading
Foresite's No. 22 Rank Signals MSSP Growth Momentum

Updated Category News Views 36

Cybersecurity rankings can be a carnival of shiny badges, but No. 22 out of 250 managed security providers is not something a serious buyer should casually brush aside. Foresite Cybersecurity landed there in MSSP Alert's 2026 survey and also made three of the program's new Prestige Top 10 lists: Best Enterprise Focused MSSP, Most Innovative MSSPs, and Fastest Growing...

Continue Reading
Cold Stone’s Holiday Menu Is a Franchisee Traffic Test

Updated Category News Views 88

Peppermint, caramel, and red velvet arrive right when dessert budgets loosen up. Cold Stone Creamery has rolled out a holiday menu running through January 5, 2027, and this is the sort of modest, practical promotion that matters more to a franchise system than the glittery language around it. Nobody should confuse two seasonal ice cream flavors with a corporate...

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 74

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
M.O.L.I.F.E. Brings Community Inclusion Into Public View

Updated Category News Views 23

A food pantry can reveal more about inclusion than a polished mission statement ever will. M.O.L.I.F.E., Inc. is set to be featured in an educational segment of All Access with Andy Garcia, and the useful part of this story is not the celebrity-host packaging. It is the organization’s insistence that employment, independent living, day programming, residential support,...

Continue Reading

Top 5 Most Recently Viewed Articles

Arasan Chip Systems Unveils Advanced eUSB2 Solutions for IoT

Updated Category News Views 300

Arasan's Innovative USB2 Solutions Now Available Arasan Chip Systems, a recognized leader in semiconductor intellectual property for mobile and automotive systems on chips (SoCs), has announced the launch of its new Embedded USB2 (eUSB2) IP Core. This cutting-edge technology aims to empower a wide range of electronic devices with efficient connectivity options. Targeting...

Continue Reading
Class Action Filed Against MongoDB: Key Insights and Impacts

Updated Category News Views 98

Overview of the Class Action Lawsuit Against MongoDB Pomerantz LLP has recently brought attention to a significant legal issue concerning MongoDB, Inc. (NASDAQ: MDB). The law firm has filed a class action lawsuit that raises serious questions about the company's compliance with securities laws and the potential consequences for investors. Allegations Explained This...

Continue Reading
Rycor LLC's Strategic Push in Commercial Heating Solutions

Updated Category News Views 136

Expanding Horizons: Rycor LLC Enters Commercial Market RYCOR LLC, well-known as the Northeast's authority in energy-efficient residential mini-splits, is broadening its horizons to embrace the commercial heating and cooling sector. This strategic move represents a significant enhancement in their service offerings, targeting multi-family housing developments, office...

Continue Reading
Successful Charity Ride Brings Community Together for a Cause

Updated Category News Views 148

Second Annual Solstice Century Ride Makes a Big Impact During the longest day of the year, fifty-two enthusiastic riders took on a 100-mile challenge as they participated in the second annual Solstice Century Ride. The event, held at the picturesque Whalon Lake Forest Preserve, proved to be more than just a cycling challenge; it became a powerful avenue for community...

Continue Reading
QuickBooks' Intelligent AI Tool Revolutionizes Business Insights

Updated Category News Views 126

Revolutionizing Business Insights with Intelligent AI In today's fast-paced business environment, understanding how to leverage technology for better decision-making is crucial. Enter QuickBooks' Intelligent AI Dashboard Agent, a powerful tool that has been recognized by industry experts as the best all-in-one solution for real-time business insights in 2025. This...

Continue Reading